TLX 6-K
Telix Pharmaceuticals Ltd (TLX)
6-K
2026-08-20
For: 2026-06-30
View Original
Added on
August 20, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of August, 2026
Commission File Number: 001-42128
(Translation of registrant’s name into English)
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-
F.
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
On August 20, 2026 (Melbourne, Australia), Telix Pharmaceuticals Limited ( “Telix”) filed the following
announcements with the Australian Securities Exchange titled: (i) “Telix H1 2026 Results Presentation,” (ii) “Telix
H1 2026 Appendix 4D and Interim Report,” and (iii) “Telix H1 2026 Results Announcement,” copies of which are
attached to this Form 6-K as Exhibit 99.1, Exhibit 99.2, and Exhibit 99.3, respectively.
Also attached as Exhibit 99.4 to this Form 6-K, are copies of Telix’s unaudited interim consolidated financial
statements for the half-year ended June 30, 2026, and the related Operating and Financial Review discussion for the
half-year ended June 30, 2026, formatted in Extensible Business Reporting Language (“XBRL”).
Exhibits 99.2 and 99.4 are incorporated by reference into Telix’s Registration Statement on Form F-3ASR (File No.
333-293611) and Registration Statement on Form S-8 (File No. 333-283917).
Telix H1 2026 Results Presentation | |
Telix H1 2026 Appendix 4D and Interim Report | |
Telix H1 2026 Results Announcement | |
Telix Half-Year 2026 Operating and Financial Review and Unaudited Interim Consolidated Financial Statements | |
101.INS | Inline XBRL Instance Document |
101.SCH | Inline XBRL Taxonomy Extension Scheme Linkbase Document |
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
Telix Pharmaceuticals Limited | |||
Date: | August 20, 2026 | By: | /s/ Christian Krautkramer |
Name: Christian Krautkramer | |||
Title: Group General Counsel | |||